Top 3 Health Care Stocks That May Crash This Quarter
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年7月3日，醫療保健板塊的三隻股票可能對那些將動量視爲其交易決策關鍵標準的投資者發出真正警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一種動量指標，它將股票在股價上升的日子裏的強度與在股價下跌的日子裏的強度進行比較。與股票價格的走勢相比，它可以讓交易員更好地了解股票在短期內的表現。當RSI高於70時，資產通常被認爲是超買的，據Benzinga Pro稱。
Here's the latest list of major overbought players in this sector.
以下是行業中超買的主要股票列表。
Harrow Inc (NASDAQ:HROW)
Harrow股份有限公司（NASDAQ：harrow）
- On June 21, Craig-Hallum analyst Chase Knickerbocker maintained Harrow with a Buy and raised the price target from $26 to $30. The company's stock gained around 22% over the past month and has a 52-week high of $22.63.
- RSI Value: 75.75
- HROW Price Action: Shares of Harrow fell 1% to close at $20.85 on Tuesday.
- 6月21日，Craig-Hallum分析師Chase Knickerbocker建議買入Harrow股份有限公司，並將價格目標從26美元上調至30美元。該公司股票過去一個月上漲了約22%，52周最高價爲22.63美元。
- RSI指標: 75.75
- Harrow的股價走勢: Harrow的股價在週二下跌1%，收於20.85美元。
Longboard Pharmaceuticals Inc (NASDAQ:LBPH)
長板藥業股份有限公司（NASDAQ：LBPH）
- On July 1, Longboard Pharmaceuticals said the FDA granted breakthrough therapy designation for bexicaserin. The company's stock gained around 47% over the past five days and has a 52-week high of $33.74.
- RSI Value: 84.20
- LBPH Price Action: Shares of Longboard Pharmaceuticals closed at $30.74 on Tuesday.
- 7月1日，長板藥業表示，美國食品和藥物管理局(FDA)授予其bexicaserin突破性療法指定。公司股票過去五天上漲約47%，52周最高價爲33.74美元。
- RSI指標: 84.20
- LBPH的股價走勢: 長板藥業的股票週二收盤價爲30.74美元。
Eli Lilly And Co (NYSE:LLY)
Eli Lilly And Co（NYSE: LLY）
- On July 2, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's Alzheimer's treatment, "Kisunla." The company's stock gained around 10% over the past month and has a 52-week high of $916.83.
- RSI Value: 74.03
- LLY Price Action: Shares of Eli Lilly closed at $906.71 on Tuesday.
- 7月2日，美國食品藥品監督管理局(FDA)已批准禮來公司（Eli Lilly and Company）的阿爾茨海默病治療藥物“基舒利”。“基舒利”的股價上漲約10%，52周最高價爲916.83美元。
- RSI指標: 74.03
- LLY的股價走勢: 艾默生的股票週二收盤價爲906.71美元。
Read More: Tesla To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Wednesday
更多閱讀：特斯拉將上漲約30%?以下是週三10個頂尖分析師的預測
譯文內容由第三人軟體翻譯。